Discovery of Novel Proteasome Inhibitors Using a High-Content Cell-Based Screening System by Lavelin, Irena et al.
Discovery of Novel Proteasome Inhibitors Using a High-
Content Cell-Based Screening System
Irena Lavelin
1, Avital Beer
2, Zvi Kam
1, Varda Rotter
1, Moshe Oren
1, Ami Navon
2, Benjamin Geiger
1*
1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel, 2Department of Biological Regulation, Weizmann Institute of Science, Rehovot,
Israel
Abstract
The regulated degradation of damaged or misfolded proteins, as well as down-regulation of key signaling proteins, within
eukaryotic and bacterial cells is catalyzed primarily by large, ATP-dependent multimeric proteolytic complexes, termed
proteasomes. Inhibition of proteasomal activity affects a wide variety of physiological and pathological processes, and was
found to be particularly effective for cancer therapy. We report here on the development of a novel high throughput assay
for proteasome inhibition using a unique, highly sensitive live-cell screening, based on the cytoplasm-to-nucleus
translocation of a fluorescent proteasome inhibition reporter (PIR) protein, consisting of nuclear localization signal-deficient
p53 derivative. We further show here that mdm2, a key negative regulator of p53 plays a key role in the accumulation of PIR
in the nucleus upon proteasome inhibition. Using this assay, we have screened the NCI Diversity Set library, containing
1,992 low molecular weight synthetic compounds, and identified four proteasome inhibitors. The special features of the
current screen, compared to those of other approaches are discussed.
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Introduction
The proteasome is the major proteolytic complex, responsible,
in eukaryotic cells, for the degradation of a multitude of cellular
proteins. This multi-protein complex, present in both the
cytoplasm and the nucleus, catalyzes the ATP-dependent
proteolysis of short-lived regulatory proteins, as well as the rapid
elimination of damaged and abnormal proteins [1,2]. The 26S
proteasome is a large complex of ,2.5 MDa. Based on
biochemical analyses, this complex can be dissociated into two
functionally distinct subcomplexes, the 20S core particle (CP)
which is the proteolytic component, and the 19S regulatory
particle (RP), that is responsible for recognizing, unfolding, and
translocating polyubiquitinated substrates into the 20S CP, where
they are degraded.
The 20S CP is a 670 kDa barrel-shaped protein complex made
up of four stacked, seven-membered rings (467 subunits), two
outer a rings and two inner b rings (a1-7b1-7b1-7a1-7). The two
matching a rings are situated in the outer rims of the barrel, facing
the 19S regulatory complex. The proteolytic active sites are
located on the two identical b-rings, which are positioned in the
center of the 20S complex [3,4]. In eukaryotes, the catalytic
activities of the proteasomes are confined to only three of the b-
subunits. Although proteasomes can hydrolyze the amide bonds
between most amino acids, proteolytic activities measured using
fluorogenic substrates define three distinct (although not conclu-
sive) cleavage preferences [5]: b2 possesses tryptic activity (i.e.,
cleaving after basic residues); b5 displays chymotryptic activity
(i.e., cleaving after hydrophobic residues); and b1 has ‘‘caspase-
like’’ or ‘‘post-acidic’’ activity. In all three active b-subunits,
proteolytic activity is associated with their N-terminal threonine
residue, which acts as a nucleophile in peptide-bond hydrolysis.
The use of proteasome inhibitors as drug candidates emerged
from the observation that at specific concentrations, they can
induce apoptosis in certain leukemia- and lymphoma-derived cells
[6,7] without similarly affecting their non-transformed counter-
parts. Further development and clinical trials led to the approval of
the modified boronic dipeptide Pyz-Phe-boroLeu, known as
Bortezomib or VelcadeH, as a drug for the treatment of multiple
myeloma [8,9,10,11]. Most synthetic proteasome inhibitors are
short peptides that mimic protein substrates. Typically, the
pharmacophore that reacts with and inhibits the threonine residue
in the 20S proteasome’s active site is bound to the carboxyl residue
of the peptide [12]. Some of the typical synthetic inhibitors are
peptide aldehydes, peptide vinyl sulfones, peptide boronates, and
peptide epoxyketones [for review, see [13]]. Most notable among
the natural, bacterially derived non-peptide inhibitors is claso-
lactacystin-b-lactone (Omuralide) [14]. Related drugs such as
Salinosporamide A (NPI-0052) and Carfilzomib (PR-171) are
currently in advanced clinical trials [15,16,17]. However, despite
the extensive efforts invested in proteasome inhibitor development,
there is a growing need for novel inhibitory molecules, due to the
emergence of drug-resistant cells and the variable effects of existing
inhibitors on different cells.
Most of the current assays for proteasome inhibition are based
on cell-free assays [18,19], which require purification of 26S or
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principle, be adapted to high-throughput screens, yet they may fail
to predict the inhibitory activity in live cells. To overcome this
problem, cell-based screens have been incorporated into the drug
discovery process. For example, a modified ‘‘classical’’ method for
measurement of the chymotrypsin-like, trypsin-like, or caspase-like
proteasome activities in cultured cells [20] is currently available
from Promega Corporation. A number of fluorescent reporter
molecules have been also usefully employed to monitor the activity
of the proteasome. Dantuma et al constructed a fusion of GFP to
Ubiquitin (Ubi[G76V]-GFP) using a standard peptide bond at the
N-terminus [21], Another proteasome sensor construct, which is a
GFP fusion to an artificial peptide, CL1, identified in yeast has
been designed by Bence et al ([22]. The Andreatta group and BD
Biosciences Clontech has introduced a sensor cell line expressing a
GFP fusion protein with a fragment of the mouse ornithine
decarboxylase (MODC), which is degraded by the proteasome
without the requirement for ubiquitination [23]. An additional
reporter cell line, based on the stable expression of a p27
kip1-GFP
fusion was recently employd for the discovery of a novel
proteasome inhibitor, argyrin A [24]. The common feature of
most of these GFP-fused reporters is that they are based on
proteins rapidly degraded by the proteasome under normal
conditions, leading to very low fluorescence of the cells, while
following inhibition of proteasome activity, the overall fluorescent
signal of the cells rapidly increases as a result of accumulation of
the reporter proteins.
In this article, we describe a novel, image-based screening
approach, which utilizes an H1299 reporter cell line, stably
expressing a fluorescent ‘‘Proteasome Inhibition Reporter’’ (PIR)
protein. The screen is based on the finding that upon inhibition of
proteasomal activity, this fluorescent reporter molecule translo-
cates from the cytoplasm to the nucleus. Our findings demonstrate
that this approach is highly sensitive, and compatible with high
throughput microscopy. In the screen reported herein, we tested
the Diversity Set of the NIH/NCI chemical library, and identified
four compounds with pronounced proteasome inhibitory activity,
three of which are novel inhibitors.
Materials and Methods
DNA Constructs, Generation of a Stable Reporter Cell
Line and Transient Transfection
To construct a YFP-tagged Proteasome Inhibitor Reporter
(PIR) protein, cDNA encoding a full-length human p53 R175H
mutant was amplified by PCR from a cDNA clone, and three
consecutive lysine residues in the bipartite Nuclear Localization
Signal (NLS) were replaced with alanines by PCR-based, site-
directed mutagenesis [25] [26]. The DNA fragment was cloned
into the BglII and NotI sites of pLPCX retroviral vector (Clontech)
in-frame to the N-terminus of the yellow fluorescent protein (YFP),
using the NotI/ClaI restriction sites. The PIR protein was
expressed in an H1299 non-small cell lung carcinoma cell line,
following retroviral infection, and the cells were cultured in RPMI
1640 medium containing 10% fetal bovine serum, 2 mM
glutamine and 1% penicillin-streptomycin (all from Sigma-
Aldrich) in a humidified atmosphere of 5% CO2 at 37uC.
Fluorescent cells were isolated by flow cytometry, and single-cell
cloning was used to generate a morphologically uniform cell
population.
Plasmids for the expression of human MDM2 were kindly
provided by B. Vogelstein (wild type MDM2), A. Levine [MDM2
D9-58] and A. Ciechanover [MDM2 Ser 440]. Transfections
employing plasmid DNA were carried out using Lipofectamine
2000
TM reagent (Invitrogen) as per the manufacturer’s instruc-
tions. For RNA interference, PIR cells were transfected with 50
pM control or MDM2 siRNA oligonucleotides (Dharmacon, ON-
TARGETplus SMARTpool), with Dharmafect 2 (Dharmacon)
according to the manufacturer’s protocol.
Immunofluorescence Microscopy
Cells were cultured on glass coverslips, fixed, and permeabilized
for 2 min in phosphate-buffered saline (PBS) containing 0.5%
Triton X-100 and 3% formaldehyde, and post-fixed with 3%
formaldehyde in PBS for 30 min. The cells were then rinsed and
stained with polyclonal anti-b-catenin antibody (Sigma) or a
mixture of anti-MDM2 monoclonal antibodies SMP14, 2A10, and
4B11 for 1 h (hybridoma cells were kindly provided by A. Levine),
washed, and further incubated with Cy3-conjugated goat anti-
mouse IgG (Enco). Images were acquired using the DeltaVision
system (Applied Precision Inc.).
Compound Library
The chemical compound library screened here for proteasomal
inhibitors consisted of the NCI Diversity Set, containing 1,992 low
molecular weight synthetic compounds selected from and
representing nearly 140,000 compounds available from the NCI
DTP chemical library (http://dtp.nci.nih.gov/branches/dscb/
diversity_explanation.html).
The library compounds were dissolved in dimethyl sulfoxide
(DMSO) to a concentration of 10 mM, placed in 96-well plates,
and stored at 270uC for future use.
Image-Based Screening Assay for Proteasome Activity
PIR-expressing H1299 cells were seeded at a density of 800 cells
per well in 384-well assay plates (F-bottom, mClear, black, tissue-
culture-treated) (Greiner Bio-One). Cells were cultured for 24 h
and treated with the library compounds at two concentrations (1
and 10 mM) in RPMI 1640. In each assay plate, cells in 24 wells
treated with 0.2% DMSO alone were used as controls. As a
positive control, 1 mM MG132 was added to a single column of
the assay plate. Following 12 hours of incubation, cells were fixed
in 3% paraformaldehyde for 20 min, then washed with PBS and
screened for localization of the PIR protein.
Microscope Automation and Image Processing
WiScan
TM Cell Imaging System (Idea Bio-Medical) was used
for this screen [27]. The system is based on an IX71 microscope
(Olympus), equipped with a fast laser AutoFocus device [28] and
an automated stage. Thirty-six fields were acquired from every
well using a 60x/0.9 air objective, stored, and tiled into montages
to detect consistent effects. Scoring of the nuclear translocation of
the fluorescent PIR protein was carried out manually.
In Vitro Proteasome Activity Assay
For measuring proteasome activity, purified 20S or 26S
proteasomes prepared from rabbit muscles were incubated at a
final concentration of 16 nM, with 100 mM fluorogenic 7-amido-
4-methylcoumarin (AMC) tetrapeptide substrate Suc-LLVY-AMC
(Bachem) and the stated concentration of the hit compounds in the
presence of 100 ml of assay buffer (50 mM Hepes, 5 mM MgCl2,
2 mM ATP and 1 mM DTT). The well-documented proteasomal
inhibitor MG132 was used as a positive control, and an equivalent
volume of solvent as a negative control. The time-dependent
increase of hydrolyzed AMC groups was measured in a 96-well
plate equilibrated to 37uC, using a Varioscan multi-well plate
reader (Thermo Fisher Scientific, Inc.) in a kinetic mode, in which
Proteasome Inhibitors Screen
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wavelength was 370 nm; fluorescence emission was recorded at
465 nm.
Immunoblotting
H1299-PIR cells were lysed with radioimmune precipitation
assay buffer (1% NP-40, 1% sodium deoxycholate, 0.1% SDS,
150 mM NaCl, 50 mM Tris, pH 8.0) containing a protease
inhibitor cocktail from Roche Applied Science. Protein extracts
were subjected to 8% SDS-PAGE, transferred to a nitrocellulose
membrane (Whatman), and probed with monoclonal anti-p53
(DO1, Santa Cruz Biotechnology), anti-ubiquitin (Covance), anti-
b-catenin (Sigma) and anti-b-tubulin (Sigma) primary antibodies.
For sub-cellular fractionation, cells were harvested and
resuspended in ice-cold hypotonic lysis buffer [10 mM HEPES
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, supplement-
ed with a complete protease inhibitor cocktail (Roche)], incubated
on ice for 15 min, then NP40 was added, to a final concentration
of 0.6%. The samples were vortexed for 10 s and immediately
centrifuged at 12,000 g for 30 s. The supernatant (cytoplasmic
fraction) was transferred to a fresh tube. The nuclei pellet was
washed once with hypotonic lysis buffer, and lysed with SDS
sample buffer (100 mM Tris–HCl pH 6.8, 2% SDS, 100 mm
DTT, and 10% glycerol).
Cell Viability Assay
The effect of each hit compound on cell viability was tested at
11 different concentrations, ranging from 0.1–100 mM. PIR cells
were plated onto 384-well microplates for 24 hours, and then
treated for 48 h with the library compounds. Cell viability was
determined using the colorimetric AlamarBlueH (Invitrogen)
viability assay, according to the manufacturer’s instructions.
Results are expressed as GI50; namely, the compound concentra-
tion that reduces the AlamarBlueH score by 50%, compared to
untreated controls.
Results
Development of an H1299-PIR Reporter Cell Line and Its
Application for an Image-Based, High-Throughput
Screening for Proteasome Inhibitors
The PIR protein, used here for proteasome inhibitor screening,
was constructed of yellow fluorescent protein (YFP) fused to the C-
terminus of the human p53 R175H mutant. The cytoplasm-to-
nucleus transport of this p53 mutant was attenuated by additional
triple mutation in the bipartite NLS in which three consecutive
lysine residues were replaced with alanines (K319A, K320A, and
K321A), as described by O’Keefe et al [29]. In agreement with
previous reports, under normal cell culture conditions, this point
mutation leads to cytoplasmic localization of the PIR protein in
H1299 cells [29,30], confirming that the three basic residues at
position 319–321 are indeed part of a nuclear localization signal.
However, upon treatment with known proteasome inhibitors (e.g.
MG132, Bortezomib and ALLN), PIR translocates into the
nucleus in a manner reminiscent of p53 mutated in its NLS
(Fig. 1B upper panel) [31]. b-catenin, whose cellular levels are
primarily regulated by the proteasome, underwent similar nuclear
translocation in response to proteasome inhibition (Fig. 1B, lower
panel), yet this was accompanied by significant stabilization and
increase in its quantity [32] unlike PIR, whose overall levels did
not markedly change. To validate these results, we quantified the
levels of PIR in the nuclear and cytoplasmic fractions of treated
and control H1299-PIR cells using immunoblotting. This assay
confirmed our microscopy-based observation, and pointed to a
,3-fold increase in the nuclear/cytoplasmic ratio of PIR, in
response to MG132 treatment (Fig. 1C).
To assess the sensitivity of the PIR cell-based assay, H1299-PIR
cells were incubated for 8 hours with different concentrations
(0.01–10 mM) of known proteasome inhibitors (MG132 and
Bortezomib). The cells were then fixed and scored for nuclear
translocation of PIR. The score (EC50) refers to the concentration
of inhibitor needed to induce nuclear translocation of PIR in 50%
of the treated cells. This test indicated that in our assay, the EC50
values for MG132 and Bortezomib were 0.5 mM, and 0.05 mM,
respectively. These values favorably compare with those reported
for other detection systems, such as the commercial Living Colors
HEK 293 ZsGreen Proteasome Sensor system (Clontech), which
detects MG132 at 2.5 mM (after 20 hours of treatment using flow
cytometry) [23], or for the Ubi[G76V]-GFP-based reporter system
(BioImage), in which the reported EC50 value for MG-132 was
approximately 1.0 mM [21]. Thus, H1299-PIR cells appear to be
sensitive reporters, capable of detecting the activity of proteasome
inhibitors in a cell-based assay.
Nuclear Accumulation of Endogenous MDM2 in
Response to Proteasome Inhibition Is Responsible for PIR
Nuclear Translocation
To further characterize the mode of PIR nuclear translocation
upon proteasome inhibition, we have considered the possibility
that proteasome-sensitive p53 binding proteins, are responsible for
carrying PIR into the nucleus. Towards this end, MDM2, a p53
E3 ubiquitin ligase and a known target of proteasome-dependent
degradation, was transfected into PIR cells, and its localization was
assessed by immunofuorescence microscopy. As expected, endog-
enous MDM2 labeling in the PIR-H1299 cells was relatively faint
and mostly nuclear while PIR was mainly localized to the
cytoplasm (Figure 2a). In contrast, in the cells transfected with wild
type MDM2, both the fluorescent PIR and MDM2 translocated to
the nucleus. This suggests that MDM2 can transport NLS-
deficient PIR from the cytoplasm into the nucleus, perhaps via the
NLS of MDM2, consistently with previous studies suggesting that
MDM2 can promote the nuclear import of DNLS p53 [31].
Interestingly, PIR remained cytoplasmic in cells over-expressing a
mutated MDM2 lacking the p53 binding site (MDM2 D 9-58),
suggesting that the interaction between the two proteins is needed
for their cotranslocation to the nucleus. On other hand, MDM2
mutant with point mutation that abolishes its E3 ubiquitin ligase
function (MDM2 Ser440) induced PIR nuclear localization similar
to the wild type molecule.
To check whether MDM2 expression is critical for PIR nuclear
translocation, we performed siRNA-mediated knockdown of
MDM2 expression in PIR-cells, and then treated the cells with
proteasome inhibitors (Figure 2b). It was found that when MDM2
levels in the knocked-down cells were reduced, PIR remained
cytoplasmic even following treatment with proteasome inhibitors,
indicating that MDM2 is an essential player in the nuclear
localization of NLS-deficient PIR.
Screening for Novel Proteasome Inhibitors in the
Diversity Set of the NIH/NCI Chemical Library
To assess the potential use of the cytoplasm-to-nucleus transloca-
tion ofPIR in high-throughput, microscopy-based screening for novel
proteasome inhibitors, we tested 1,992 low molecular weight
compounds comprising the NCI Diversity Set chemical library. A
flow chart depicting the screening procedure is shown in Figure 3,
and described in the Experimental Procedures. Following the initial
automated screen, the images of the affected cells were inspected
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compounds were tested at multiple concentrations, and directly
compared to the well-established proteasome inhibitor MG132. This
procedure resulted in the discovery of four compounds that induced
nuclear translocation of PIR, indicating a hit rate of ,0.2%. As
summarized in Table 1, all four compounds detected in the primary
screen were confirmed by manual inspection.
Biochemical Validation of the Inhibitory Effects of the Hit
Compounds
One characteristic outcome of proteasome inhibition is the
accumulation of ubiquitinated proteins in the treated cells. To
monitor the levels of ubiquitinated proteins that accumulated upon
incubation with the novel inhibitors detected in our screen,
H1299-PIR cells were treated with each of the inhibitors for
Figure 1. Engineering and validation of the PIR reporter system. (A) Schematic representation of the PIR protein. PIR consists of yellow
fluorescent protein (YFP) fused to the C-terminus of the human p53 mutant R175H, carrying a triple mutation in the bipartite NLS in which three
consecutive lysine residues were replaced with alanines K319A, K320A, and K321A. (B) Nuclear accumulation of the PIR protein upon treatment with
proteasome inhibitors. PIR cells were exposed to MG132, Bortezomib, and ALLN at the indicated concentrations for 6 h. PIR-associated YFP-
fluorescence (upper panel) and immunostaining with anti-b-catenin antibody (lower panel) are seen. (C) PIR cells were incubated for 6 h without
proteasome inhibitor (control), or with 10 mM MG132. Fractionated cytoplasm and nuclear lysates were analyzed by Western blot with anti-p53
antibody. A band corresponding to PIR was detected in the nuclear fraction only following treatment with MG132.
doi:10.1371/journal.pone.0008503.g001
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Following incubation, cell extracts were analyzed by Western blot,
using anti-ubiquitin and anti-b-catenin antibodies. As shown in
Fig. 4A&B, accumulation of endogenous polyubiquitinated
proteins, as well as elevated levels of b-catenin (a known target
of the proteasome), at varying degrees, were caused by all four
inhibitors, confirming their inhibitory effect on proteasomal
degradation. The hit compounds NSC321206 (at a concentration
of 0.15 mM) and NSC310551 (0.3 mM) were the most effective,
demonstrating inhibitory activity comparable to that of 5 mM
MG132. NSC99671 and NSC3907 (50 mM and 20 mM, respec-
tively) displayed less of an inhibitory effect. It is noteworthy that
the same concentrations that induced nuclear transport in the PIR
assay, also resulted in accumulation of polyubiquitinated proteins
and stabilization of b-catenin. Moreover, the potency of
proteasomal inhibition, judged by these criteria, coincides nicely
with the magnitude of the nuclear fluorescence signal detected in
the PIR cell-based assay, upon inhibition with the different hit
compounds.
To directly test the capacity of the four compounds to inhibit
activity in mammalian proteasomes, we performed an in vitro
activity assay in which the hit compounds were tested for their
effects on the degradation of the model fluorogenic tetrapeptide
LLVY-AMC by purified rabbit 26S proteasomes. As seen in
Fig. 4C, all four compounds inhibited proteasomal degradation to
varying degrees. Both NSC310551 and NSC321206 showed levels
of inhibition comparable to that of MG132, with NSC321206
being the most effective inhibitor. NSC99671 displayed a
moderate inhibitory effect, and NSC3907 had only a minor
effect. The low potency of NSC3907 in inhibiting the purified
Figure 2. MDM2 promotes PIR nuclear translocation. (A) Overexpression of MDM2 results on the PIR nuclear localization without additional
stimuli. PIR cells were transfected with wild-type MDM2, MDM2 mutant deficient on p53 binding (D 9-58), or MDM2 mutant with abolished E3 ligase
site (Ser 440). Cells expressing both p53 and MDM2 were visualized by immunofuorescence staining with the anti-MDM2 monoclonal antibodies. PIR
has a nuclear localization in the cells expressing wt MDM2 and MDM2 (Ser 440), and remains cytoplasmic in the cells transfected with MDM2 (D 9-58).
(B) Mdm2 siRNA prevents bortezomide–induced translocation of PIR to the nucleus. PIR cells were transiently transfected with 200 pmol control-
siRNA or Mdm2-siRNA. Forty-eight hours after transfection, bortezomide (0.1 mM) was added for an additional 6 h, and immunofuorescence staining
for MDM2 was performed as described in Materials and Methods.
doi:10.1371/journal.pone.0008503.g002
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that this molecule (8-Quinolinol salicylate) can specifically inhibit
the chymotryptic activity of the proteasome only in complex with
intracellular copper. The fact that this compound was still picked
up by our screen reflects an advantage of this cell-based assay.
Effect of the Novel Proteasome Inhibitors on Cell Viability
Proteasome inhibitors are known to be particularly cytotoxic to
malignant cells via multiple mechanisms [7,35]. To directly test
the effects of the new proteasome inhibitors discovered in this
study on cell viability, we treated PIR-expressing H1299 cells for
48 h with each of the four compounds, at a wide range of
concentrations, ranging from 0.1 to 100 mM. The cells were then
subjected to an Alamar Blue viability assay, which quantifies the
number of metabolically active cells. As shown in Fig. 5, all four
compounds affect cell viability, or inhibit the growth of PIR-
H1299 cells (independent of the presence of PIR), at different
concentrations. NSC3907 and NSC99671 exhibited a relatively
weak growth inhibition effect, with GI50 values of 47 mM and
96 mM, respectively, while NSC310551 and NSC321206 dis-
played a considerably stronger effect, with GI50 values of 0.27 mM
and 0.17 mM, respectively. For all proteasome inhibitors examined
in this screen, there was a high correlation between proteasomal
inhibitory activity and cell viability.
In view of previous reports, indicating that malignant cells are
significantly more sensitive to proteasome inhibition than their
normal counterparts [7,36], we compared the effect of the most
effective inhibitory compound, NSC321206, toward normal breast
epithelial cell line (MCF10A) and malignant breast carcinoma cells
(MDM-MB-231) cell lines. As shown in Fig. S1, NSC321206
effectively eliminated all MDA-MB-231 cells at a concentration of
1 mM (GI50 value of 0.4 mM), while the non-malignant breast
epithelial cell line (MCF10A) were only partially affected, at a
considerably higher concentration of this compound.
To gain insights into the effects of our hit compounds on a wide
variety of cells, we explored the published information on the
effects of these compounds on the NCI-60 panel of human tumor
cell lines used in the NCI Developmental Therapeutics Program
(DTP) (http://dtp.nci.nih.gov). As seen in Figure S2, the four hit
compounds showed cytotoxic effects (log10 GI50 ,24.0) against a
variety of cell lines, whereas NSC321206 and NSC310551
demonstrated high cytotoxicity in vitro against all tested human
cancer cell lines in the panel, with average negative log10 GI50
values of 7.2 and 6.6, respectively. The activity of NSC3907 was
much lower, with a mean overall – log10 GI50 value of 5.3.
NSC99671 was non- toxic for most of the lines (overall –log10
GI50 of 4.1). The most sensitive cell lines for all hit compounds
were the leukemia cells, with overall -log10 GI50 equaling 7.73 for
NSC321206, 7.028 for NSC310551, 6.249 for NSC3907, and
4.473 for NSC9967. These initial findings corroborate our in vitro
results, and directly demonstrate the use of our novel proteasomal
inhibitors as potential therapeutic agents in cancer.
Discussion
Presently, few approaches for the high-throughput discovery
of proteasome inhibitors exist [18,19,20], those that do, are
mostly based on the use of biochemical techniques. Cell-based/
image-based assays enables evaluation of potential proteasomal
inhibitors that may not be detected using purified proteasomes
and have several other advantages such as demonstrating that
active compounds are cell-permeable and are sensitive to effects
at multiple targets and nodes within a given pathway, as
opposed to a strict cell-free assay that focuses on one particular
target, such as degradation of a particular substrate by a purified
proteasome. The main motivation directing the development of
PIR was to establish a method enabling the assessment of
Figure 3. A flow chart of the screening procedure. For the
screening assay, H1299-PIR reporter cells were plated in 384-well plates
for 24 h and treated with compounds of the NCI Diversity Set library at
two concentrations (1 and 10 mM), one compound per well. Following
12 hours of incubation, cells were fixed in 3% paraformaldehyde and
screened for PIR cellular localization with WiScan
TM automated
microscope system. Acquired images were analyzed for PIR nuclear
translocation, and selected hits were confirmed by microscopy-based
and biochemical methods, and tested for compound cytotoxicity.
doi:10.1371/journal.pone.0008503.g003
Table 1. The hit compounds identified in the PIR screen as potent proteasomal inhibitors.
NSC3907 NSC99671 NSC310551 NSC321206
Chemical name 8-Hydroxyquinoline
salicylate
2-[2-[(1,3-dimethyl-2-oxo-6-
sulfanylidene-7H-purin-8-yl)sulfanyl]
ethyl]isoindole-1,3-dione
copper; [(6-methylpyridin-2-
yl)methylideneamino]-[methylsulfanyl
(sulfoniu mylidene]methyl) azanide
bromocopper; (dipyridin-2-
ylmethylideneamino)-
[methylsulfanyl(sulfoniumylidene)
methyl]azanide
Molecular formula C16H13NO4 C17H15N5O3S2 C18H22CuN6S4 C13H12BrCuN4S2
EC50 5 mM 15 mM 0.25 mM 0.1 mM
doi:10.1371/journal.pone.0008503.t001
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unequivocal translocation of a fluorescent reporter protein from
the cytoplasm to the nucleus upon proteasomal inhibition,
without grossly affecting its overall levels. We found this
approach to be highly specific, with essentially no false positives,
in contrast to existing cell-based screens for proteasomal
inhibitors that monitor the accumulation of fluorescent signals
from direct proteasomal substrates [21,22,23], that appear to be
sensitive to autofluorescence and to the fluorescence-quenching
e f f e c t so ft h es c r e e n i n gm o l e c u l e s ,a sw e l la st ov a r i a t i o n si nc e l l
geometry, some of which may be induced, directly or indirectly,
by proteasomal inhibition.
The design of the PIR reporter protein is based on a p53
R175H mutant which, in contrast to the short-lived, WT p53, has
a significantly longer half-life (several hours), presumably due to
its reduced susceptibility to proteasomal degradation [37]. As a
result, the overall concentration of PIR in cells is only marginally
affected by treatment with proteasomal inhibitors such as MG132
(Fig. 1C). In the PIR assay, monitoring proteasomal inhibition is
based on intracellular translocation of the reporter protein from
the cytoplasm to the nucleus, in response to proteasomal
inhibition. It is noteworthy that PIR was found to be particularly
suitable for high throughput screening for proteasomal inhibitors,
due to the unambiguous quantification of nuclear vs. cytoplasmic
fluorescence.
Several proteins such as p53, MDM2 and b-catenin were
previously reported to accumulate in the nucleus following
treatment with proteasome inhibitors [32,38,39,40,41,42].
Beyond the fact that these are all target substrates of the
ubiquitin-proteasome pathway, their translocation to the
nucleus is mediated via recognition of their NLS by cytosolic
nuclear transport receptors [apart from b-catenin, which is
imported into the nucleus by direct binding to the nuclear pore
machinery [43]]. Typically, deletion or mutation of the NLS
disrupts their nuclear import. Under normal cell culture
conditions, PIR, which is based on R175H p53 with a mutated
bipartite NLS [29], loses its ability to translocate to the nucleus
and, therefore, accumulates in the cytoplasm. Even treatment
with etoposide, which is a strong inducer of p53 cytoplasm-to-
nucleus transport, fails to promote this translocation. Our
s t u d i e sp r o v i d es o m ec l u e sa st o the mechanism underlying PIR
Figure 4. Positive hit compounds inhibit 26S proteasome. (A)
PIR cells were treated with hit compounds and MG132 for 6 hr at the
following concentrations: NSC3907 – 20 mM; NSC99671 – 50 mM;
NSC310551 – 0.3 mM; NSC321206 – 0.15 mM; and MG132 - 5 mM).
Whole cell lysates were immunoblotted for ubiquitin (upper panel) and
b-catenin (middle panel). Tubulin (lower panel) was used as an internal
loading control. (B) Quantitation of the amounts of ubiquitinated
proteins (blue) and b-catenin (red) in the absence of and upon
treatment with the different inhibitors. (C) Positive hit compounds
inhibit purified proteasome in vitro. Purified 26S proteasomes from
rabbit muscle were incubated for the indicated times in the presence of
30 mM of our positive hits (100 mM for NSC3907). MG-132 at a 5 mM
concentration served as a positive control. NSC3907 (blue), NSC99671
(green), NSC310551 (magenta), NSC321206 (orange), without treatment
(red) and MG-132 (black).
doi:10.1371/journal.pone.0008503.g004
Figure 5. Effect of the hit compounds on the viability of PIR
cells. PIR cells were treated with the active compounds for 48 hr at 11
concentrations ranging from 0.1 to 100 mM and the cells’ viability was
assessed by AlamarBlue assay. Results are expressed as the viability
ratio of treated to untreated cells and represent the mean 6 SD of 6
repeats.
doi:10.1371/journal.pone.0008503.g005
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Specifically, we propose a model suggesting that nuclear entry
of this molecule is driven by yet another protein, which is highly
sensitive to proteasomal degradation, contains a nuclear
localization domain, and is capable of piggy-backing PIR into
the nucleus. Furtheremore, we provide evidence suggesting that
this nuclear translocator of PIR is, in fact, the p53 E3 ubiquitin
ligase MDM2, which was shown to translocate into the nucleus
upon proteasome inhibition (Xirodimas et al 2001). MDM2
promotes PIR nuclear import in transiently transfected cells
over-expressing wild type MDM2, in the absence of additional
stimuli (Fig. 2). Upon proteasome inhibition, the levels of
MDM2 dramatically increase and, in turn, drive PIR into the
nucleus. We also demonstrated that the ability of MDM2 to
bind p53 is critical for such translocation, unlike its E3 ubiquitin
ligase function. Further compelling support for our model comes
from the fact that the translocation of the PIR protein to the
nucleus, induced by proteasome inhibition, is abolished by
MDM2 knockdown, confirming that the interaction between the
two proteins results in colocalization in the nucleus. This is
consistent with previous reports showing that wild type p53 (as
well as its homologue p73) and MDM2 may facilitate the
shuttling of each other from the cytoplasm into the nucleus
[31,44] and vice versa.
In conclusion, the novel cell-based screen described here
appears to be a robust and highly sensitive tool for the
identification on new proteasome inhibitors. It is based on the
stabilized MDM2-dependent accumulation of the PIR molecule in
the nucleus, and is compatible with microscopy-based high
throughput screening technology. Further characterization of the
new inhibitors discovered using this approach, as well as the
development of a combined ultra high resolution / high content
screen, based on the PIR cells, are currently underway.
Supporting Information
Figure S1 Differential effect of NSC321206 on human malig-
nant breast cells (MDM-MB-231) and human non-malignant
breast epithelial cells (MCF10A). The two cell lines were treated
with NSC321206 for 48 hr at 6 concentrations ranging from 0.025
to 2.5 mM and the viability was assessed using the AlamarBlue
assay. Results are expressed as the viability ratio of treated to
untreated cells and represent the mean 6 SD values of 6 repeats.
Found at: doi:10.1371/journal.pone.0008503.s001 (2.12 MB TIF)
Figure S2 In vitro cytotoxicity of the hit compounds on an NCI-
60 panel of human tumor cell lines. Results are based on data from
anti-cancer drug screening against the full panel of 60 human
cancer cell lines, conducted as part of the Developmental
Therapeutics Program at the National Cancer Institute (http://
dtp.nci.nih.gov). The panel is divided into nine sub-panels
representing diverse cancer cell types, including leukemia,
melanoma, and cancers of the lung, colon, kidney, ovary, breast,
prostate, and central nervous system. Results obtained with this
test are expressed as the -log of the molar concentration that
inhibited cell growth by 50% (-log GI50 .4.00 for active
compounds).
Found at: doi:10.1371/journal.pone.0008503.s002 (4.24 MB TIF)
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